HK1140479A1 - Mono-hydrochloric salts of an inhibitor of histone deacetylase - Google Patents

Mono-hydrochloric salts of an inhibitor of histone deacetylase

Info

Publication number
HK1140479A1
HK1140479A1 HK10106880.8A HK10106880A HK1140479A1 HK 1140479 A1 HK1140479 A1 HK 1140479A1 HK 10106880 A HK10106880 A HK 10106880A HK 1140479 A1 HK1140479 A1 HK 1140479A1
Authority
HK
Hong Kong
Prior art keywords
mono
inhibitor
forms
histone deacetylase
hydrochloric salts
Prior art date
Application number
HK10106880.8A
Other languages
English (en)
Inventor
Julius W J Dickens
Ioannes Nicolaos Houpis
Yolande Lydia Lang
Carina Leys
Sigrid Carl Maria Stokbroekx
Johan Erwin Edmond Weerts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38659779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1140479(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HK1140479A1 publication Critical patent/HK1140479A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK10106880.8A 2007-05-14 2010-07-15 Mono-hydrochloric salts of an inhibitor of histone deacetylase HK1140479A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91782107P 2007-05-14 2007-05-14
EP07108176 2007-05-14
PCT/EP2008/055804 WO2008138918A1 (en) 2007-05-14 2008-05-13 Mono-hydrochloric salts of an inhibitor of histone deacetylase

Publications (1)

Publication Number Publication Date
HK1140479A1 true HK1140479A1 (en) 2010-10-15

Family

ID=38659779

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10106880.8A HK1140479A1 (en) 2007-05-14 2010-07-15 Mono-hydrochloric salts of an inhibitor of histone deacetylase

Country Status (33)

Country Link
US (2) US20100130523A1 (es)
EP (1) EP2155677B1 (es)
JP (1) JP2010526851A (es)
KR (1) KR101540679B1 (es)
CN (1) CN101679256B (es)
AP (1) AP2717A (es)
AR (2) AR066550A1 (es)
AU (1) AU2008250047B2 (es)
BR (1) BRPI0811859B8 (es)
CA (1) CA2683195C (es)
CL (1) CL2008001390A1 (es)
CO (1) CO6140031A2 (es)
CR (1) CR11163A (es)
CY (1) CY1115837T1 (es)
DK (1) DK2155677T3 (es)
EA (1) EA018326B1 (es)
EC (1) ECSP099729A (es)
ES (1) ES2525456T3 (es)
HK (1) HK1140479A1 (es)
HR (1) HRP20141180T1 (es)
IL (1) IL202042A0 (es)
JO (1) JO2959B1 (es)
MX (1) MX2009012332A (es)
NZ (1) NZ599674A (es)
PA (1) PA8780301A1 (es)
PL (1) PL2155677T3 (es)
PT (1) PT2155677E (es)
RS (1) RS53672B1 (es)
SG (1) SG182986A1 (es)
SI (1) SI2155677T1 (es)
TW (1) TWI414294B (es)
UA (1) UA100510C2 (es)
WO (1) WO2008138918A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5924990B2 (ja) * 1979-11-21 1984-06-13 協和醗酵工業株式会社 新規なピペリジン誘導体
ES2175137T3 (es) 1995-12-08 2002-11-16 Janssen Pharmaceutica Nv Derivados de (imidazol-5-il)metil-2-quinolinona como inhibidores de laproteina farnesil-transferasa.
EA012584B1 (ru) * 2004-07-26 2009-10-30 Лаборатуар Сероно Са Производные n-гидроксиамида и их применение
EA010652B1 (ru) * 2004-07-28 2008-10-30 Янссен Фармацевтика Н.В. Замещенные индолильные алкиламинопроизводные в качестве новых ингибиторов гистондеацетилазы

Also Published As

Publication number Publication date
PT2155677E (pt) 2014-12-23
BRPI0811859B8 (pt) 2021-05-25
AP2009005039A0 (en) 2009-12-31
AU2008250047B2 (en) 2013-01-17
KR20100015647A (ko) 2010-02-12
NZ599674A (en) 2013-02-22
WO2008138918A1 (en) 2008-11-20
US8759519B2 (en) 2014-06-24
EA018326B1 (ru) 2013-07-30
SI2155677T1 (sl) 2015-01-30
BRPI0811859B1 (pt) 2020-02-11
EP2155677B1 (en) 2014-10-01
CL2008001390A1 (es) 2008-11-21
CA2683195A1 (en) 2008-11-20
RS53672B1 (en) 2015-04-30
ECSP099729A (es) 2009-12-28
KR101540679B1 (ko) 2015-07-30
CY1115837T1 (el) 2017-01-25
CA2683195C (en) 2016-08-09
PL2155677T3 (pl) 2015-03-31
AR066550A1 (es) 2009-08-26
CN101679256B (zh) 2013-06-26
AR118361A2 (es) 2021-09-29
JP2010526851A (ja) 2010-08-05
EP2155677A1 (en) 2010-02-24
EA200971031A1 (ru) 2010-04-30
US20120289527A1 (en) 2012-11-15
CO6140031A2 (es) 2010-03-19
AU2008250047A1 (en) 2008-11-20
HRP20141180T1 (hr) 2015-02-13
TW200914024A (en) 2009-04-01
PA8780301A1 (es) 2008-12-18
CN101679256A (zh) 2010-03-24
SG182986A1 (en) 2012-08-30
IL202042A0 (en) 2010-06-16
TWI414294B (zh) 2013-11-11
UA100510C2 (ru) 2013-01-10
ES2525456T3 (es) 2014-12-23
AP2717A (en) 2013-07-31
CR11163A (es) 2010-05-27
BRPI0811859A2 (pt) 2014-11-18
US20100130523A1 (en) 2010-05-27
JO2959B1 (en) 2016-03-15
DK2155677T3 (en) 2015-01-05
MX2009012332A (es) 2009-12-01

Similar Documents

Publication Publication Date Title
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
JO3148B1 (ar) مركب مثبط لإشارات مسار notch
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2011008634A (es) Derivados de aminotetralina composiciones farmaceuticas que los contienen y su uso en terapia.
MY170935A (en) Neprilysin inhibitors
MY172924A (en) Neprilysin inhibitors
TN2013000434A1 (en) Novel imidazole derivatives useful for the treatment of arthritis
SG191175A1 (en) Neprilysin inhibitors
MX342212B (es) Inhibidores de neprilisina.
MX343753B (es) Inhibidores de neprilisina.
IN2012DN01233A (es)
MX2009014235A (es) 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY160392A (en) Triptolide prodrugs
MX2012008328A (es) Derivados de pirazina.
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
MX2013011132A (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
GEP20125433B (en) α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT
HK1140479A1 (en) Mono-hydrochloric salts of an inhibitor of histone deacetylase
UA94042C2 (ru) Применение агомелатина в получении лекарственных средств, предназначенных для лечения синдрома смита-магениса
AU2012225365A8 (en) Peptide deformylase inhibitors